Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients

Liver International

Volumn 32, Issue 5, 2012, Pages 859-866

  Lee, Yen Chieh ^a   Chang, Chia Hsuin ^b,c   Lin, Jou Wei ^c,d   Chen, Hsi Chieh ^b   Lin, Min Shung ^a   Lai, Mei Shu ^b  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Anti inflammatory agents; Celecoxib; Cirrhosis; Gastrointestinal haemorrhage; Non steroidal; Variceal bleeding

Indexed keywords

ACEMETACIN; ACETYLSALICYLIC ACID; CELECOXIB; CORTICOSTEROID; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; KETOROLAC; MEFENAMIC ACID; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CASE STUDY; DISEASE ASSOCIATION; DRUG USE; DUODENITIS; FEMALE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL VARICEAL BLEEDING; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PEPTIC ULCER BLEEDING; RETROSPECTIVE STUDY; UPPER GASTROINTESTINAL TRACT; VARICOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COMORBIDITY; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; DUODENITIS; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; GASTRITIS; GASTROINTESTINAL DISEASES; HISTAMINE ANTAGONISTS; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; PEPTIC ULCER; PROTON PUMP INHIBITORS; PYRAZOLES; RISK ASSESSMENT; SULFONAMIDES; YOUNG ADULT;

EID: 84862794717     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02739.x     Document Type: Article

References (29)

1. Lecleire S, Di Fiore F, Merle V, et al. Acute upper gastrointestinal bleeding in patients with liver cirrhosis and in noncirrhotic patients: epidemiology and predictive factors of mortality in a prospective multicenter population-based study. J Clin Gastroenterol 2005; 39: 321-7.
2. del Olmo JA, Pena A, Serra MA, et al. Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. J Hepatol 2000; 32: 19-24.
3. D'Amico G, De Franchis R Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38: 599-612.
4. Gatta A, Merkel C, Amodio P, et al. Development and validation of a prognostic index predicting death after upper gastrointestinal bleeding in patients with liver cirrhosis: a multicenter study. Am J Gastroenterol 1994; 89: 1528-36.
5. El-Serag HB, Everhart JE Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol 2000; 95: 3566-73.
6. Chalasani N, Kahi C, Francois F, et al. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol 2003; 98: 653-9.
7. Wong LL, McFall P, Wong LMF The cost of dying of end-stage liver disease. Arch Intern Med 1997; 157: 1429-32.
8. Zaman A, Goldberg RJ, Pettit KG, et al. Cost of treating an episode of variceal bleeding in a VA setting. Am J Gastroenterol 2000; 95: 1323-30.
9. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
10. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.
11. Rostom A, Muir K, Dube C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane collaboration systematic review. Clin Gastroenterol Hepatol 2007; 5: 818-28.
12. Everhart JE, Ruhl CE Burden of digestive diseases in the United States part III: liver, biliary tract, and pancrease. Gastroenterology 2009; 136: 1134-44.
13. Lim YS, Kim WR The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 2008; 12: 733-46.
14. Chang CH, Lin JW, Chen HC, et al. Nonsteroidal anti-inflammatory drugs and risk of lower gastrointestinal adverse events: a nationwide study in Taiwan. Gut 2011; 60: 1372-78. DOI: 10.1136/gut.2010.229906 [Epub ahead of print].
15. Chang CH, Chen HC, Lin JW, et al. Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiol Drug Saf 2011; 20: 763-71.
16. Maclure M, Mittleman MA Should we use a case-crossover design? Annu Rev Public Health 2000; 21: 193-221.
17. Schneeweiss S, Sturmer T, Maclure M Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 1997; 6(Suppl 3): S51-9.
18. Kramer JR, Davila JA, Miller ED, et al. The validity of viral hepatitis and chronic liver disease diagnoses in Veterrans Affairs administrative databases. Aliment Pharmacol Ther 2007; 27: 274-82.
19. WHO Collaborating Centre for Drug Statistics Methodology. Defined daily dose: definition and general considerations. Available from, accessed 29 March 2010
20. Chandok N, Watt KD Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc 2010; 85: 451-8.
21. Burak KW, Lee SS, Beck PL Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) syndrome. Gut 2001; 49: 866-72.
22. Schafer AI Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995; 35: 209-19.
23. Garcia-Tsao G, Bosch J Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010; 362: 823-32.
24. de Ledinghen V, Mannant PR, Foucher J, et al. Non-steroidal anti-inflammatory drugs and variceal bleeding: a case-control study. J Hepatol 1996; 24: 570-3.
25. de Ledinghen V, Heresbach D, Fourdan O, et al. Anti-inflammatory drugs and variceal bleeding: a case-control study. Gut 1999; 44: 270-3.
26. Castro-Fernandez M, Sanchez-Munoz D, Galan-Jurado MV, et al. Influence of nonsteroidal antiinflammatory drugs in gastrointestinal bleeding due to gastroduodenal ulcers or erosions in patients with liver cirrhosis. Gastroenterol Hepatol 2006; 29: 11-4.
27. Yoshida H, Mamada Y, Taniai N, et al. Interactions between anti-ulcer drugs and non-steroidal anti-inflammatory drugs in cirrhotic patients with bleeding esophagogastric varices. Hepatogastroenterology 2009; 56: 1366-70.
28. Hernandez-Diaz S, Rodriguez LA Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-9.
29. Masso Gonzalez EL, Patrignani P, Tacconelli S, Garcia Rodriguez LA Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010; 62: 1592-601.